How the diabetes injection works for weight loss — and what that means for you

Why a diabetes drug became a weight-loss treatment, and why that matters to you now

The connection between diabetes injections and weight loss was not a design choice at first. Researchers developing GLP-1 receptor agonists noticed that trial participants consistently lost weight alongside their improved blood sugar, often more weight than anyone expected. That observation drove dedicated weight-management programmes, and the results changed what clinicians thought was achievable outside of surgery.

Semaglutide (sold as Wegovy for weight management) and tirzepatide (sold as Mounjaro for weight management) are the two medicines now licensed in the UK for this purpose in adults without diabetes. Both started life in diabetes research. The overlap between diabetes and weight-loss injections can be confusing, so the key point is this: the weight-loss licence and the diabetes licence are legally distinct, carry different approved doses, and come under different clinical criteria. A medicine prescribed for one purpose is not automatically appropriate for the other.

Tirzepatide goes one step further, it activates two receptors (GIP and GLP-1) rather than one, making it the only dual-agonist weight-loss medicine currently licensed in the UK, and if you are weighing up your options it is worth reading about the strongest weight loss injection available to understand how these medicines compare on clinical outcomes. In the SURMOUNT-1 trial, participants taking the highest dose lost an average of around 20–21% of their body weight over 72 weeks, as published in the New England Journal of Medicine. Those are averages from a clinical setting, individual results vary, and no outcome can be guaranteed.

What these injections actually do inside the body, the real mechanism

The short answer: they slow things down and turn the volume down on hunger. GLP-1 receptor agonists bind to receptors in the pancreas, gut, and brain. In the pancreas they support insulin release in response to food. In the gut they slow gastric emptying, food moves through more slowly, so you feel full for longer. In the brain they act on appetite-regulating centres, reducing cravings and the drive to eat.

Tirzepatide adds GIP receptor activation to that picture. GIP is a second gut hormone involved in fat storage and energy balance. Activating both pathways together appears to produce stronger appetite suppression than either pathway alone, which is broadly why the SURMOUNT-5 head-to-head trial (published in the New England Journal of Medicine, 2025) found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks.

None of this is a fat-burning shortcut. The weight loss happens because you eat less, consistently, over many months. The detailed mechanism behind weight-loss injections is worth reading if you want to understand what to expect week by week. Reduced appetite does not mean zero hunger, and the medicines work best alongside real changes to diet and activity, that combination is built into the UK licence conditions. The NHS medicines page on tirzepatide sets out what to expect in plain language.

Who this medicine suits, and where the clinical lines are drawn

This is the decision the page heading refers to. Not everyone who wants to lose weight is a suitable candidate, and the safety bar for these medicines is genuinely high. UK licensed criteria for weight management require adults to have a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, a prescriber reviews your full health history.

Several conditions make these injections unsuitable. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, and certain gastrointestinal conditions all require careful discussion. These medicines are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. They are not licensed for anyone under 18.

If you are already taking medication for diabetes, or if your GP has mentioned prediabetes, the picture around prediabetes and weight-loss injections is worth exploring before your consultation. And if you have been offered one of these medicines informally (through a friend, a social media seller, or a site that does not require clinical assessment) that is a serious red flag. The MHRA has warned publicly that fake pens sold without a prescription have caused hospitalisations. Report suspect sellers at the MHRA Yellow Card service.

Starting treatment: what the process looks like in practice

If you are clinically suitable, treatment begins at the lowest dose, 2.5mg for tirzepatide, 0.25mg for semaglutide. The starter dose exists to help your system adjust, not to produce immediate weight loss. Your prescriber then reviews progress and adjusts the dose in planned steps over several months. Telling a prescriber to skip ahead is not how it works; the titration schedule is part of the safety design.

At nume, your consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated system. If approved, the pen is dispatched the same day for free next-working-day delivery via DPD, arriving in plain, unbranded packaging. You can track it on your phone like any other DPD parcel. The pen itself is a pre-filled device; you inject once weekly into the abdomen, thigh, or upper arm, rotating the site each time. Full injection guidance is in the Patient Information Leaflet supplied with your medicine.

Our pharmacy is registered with the GPhC (premises registration 9012878, verifiable at pharmacyregulation.org). If you want to understand the broader landscape of options before starting, our overview of weight-loss injections available in the UK covers the licensed choices side by side. When you are ready to speak to a clinician, start your free consultation here.